Therapeutic use of antibodies against ENPP3
AssigneeZhejiang Shimai Pharmaceutical Co., Ltd.
InventorsZuoxiang Xiao, Jiaping Peng, Dongwen Zhou, Wei Zhou
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antibodies against ENPP3 and uses thereof, specifically monoclonal antibodies against ENPP3, bispecific antibodies against ENPP3 and CD3, nucleic acids including nucleotide sequences encoding the antibodies, vectors including the nucleic acids, and host cell including the nucleic acids or the vectors. Also disclosed are pharmaceutical compositions and conjugates including the antibodies, and therapeutic methods for using the antibodies.
Claims20
A method of treating a cancer in a human subject having the cancer, comprising administering to the human subject an effective amount of an antibody molecule that specifically binds to ENPP3 or an antigen binding fragment thereof comprising a light chain variable region (VL) and a heavy chain variable region (VH),
- wherein the VL comprises LCDRs 1-3 having the amino acid sequences as set forth in SEQ ID NOs:
- 1-3 respectively, and the VH comprises HCDRs 1-3 having the amino acid sequences as set forth in SEQ ID NOs:
- 6-8 respectively, and
- wherein the cancer is an ENPP3 positive cancer.
Dependencies are inferred from the claim text.